Physician profile
Dianne Capra
NPI 1942939129
$1,311.22
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $338 · 2023: $316 · 2024: $657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $973.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $973.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $242.34 | 2024 | |
| Silk Road Medical, INC. | $179.92 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $179.51 | 2022-2024 | Farxiga |
| Atricure, INC. | $139.14 | 2023 | |
| Edwards Lifesciences Corporation | $135.00 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $111.28 | 2023-2024 | Opsumit, Uptravi |
| E.R. Squibb & Sons, L.L.C. | $88.34 | 2022-2024 | Eliquis, Camzyos |
| Amgen INC. | $41.87 | 2023-2024 | Repatha |
| Pfizer INC. | $35.00 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $29.66 | 2024 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $27.42 | 2024 | Onpattro |
| Merck Sharp & Dohme LLC | $25.55 | 2024 | Verquvo |
| Janssen Pharmaceuticals, INC | $21.14 | 2023 | Xarelto |
| Novo Nordisk INC | $20.86 | 2024 | |
| Esperion Therapeutics, INC. | $18.65 | 2024 | Nexletol |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $15.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dianne Capra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.